`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`COALITION FOR AFFORDABLE DRUGS VI LLC,
`
`Petitioner,
`
`v.
`
`CELGENE CORPORATION
`
`Patent Owner
`
`________________
`
`Case IPR2015-01096
`Patent 6,315,720
`________________
`
`DECLARATION OF JOHN FREEMAN
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2015-01096
`
`CELGENE EXHIBIT 2068
`
`Page 1 of 5
`
`
`
`
`
`I, John Freeman, hereby declare and state as follows:
`
`1.
`
`I submit this declaration on behalf of Celgene Corporation
`
`(“Celgene”), Patent Owner of U.S. Patent No. 6,315,720 (the “’720 patent”) in
`
`connection with this inter partes review, Case IPR2015-01096.
`
`I.
`
`BACKGROUND
`
`2.
`
`I am currently the Corporate Vice President, Head of Global Drug
`
`Safety & Risk Management for Celgene Corporation. I have held this position
`
`since I became employed by Celgene in September 2005.
`
`3.
`
`In my role as Head of Global Drug Safety & Risk Management, I lead
`
`the group responsible for monitoring various safety aspects of Celgene’s products.
`
`Specifically, my team is responsible for the assessment of data concerning the safe
`
`use of Celgene’s products, both in the marketplace and in clinical development.
`
`My team works to ensure compliance with regulatory requirements with regard to
`
`the safety profile of Celgene’s products, and to make safety information available
`
`to various regulatory agencies. These responsibilities involve the development and
`
`implementation of procedures relating to the restricted distribution of Celgene’s
`
`products pursuant to regulatory requirements.
`
`4.
`
`Prior to joining Celgene, I served as Global Head of Drug Safety
`
`Operations at Amgen, where I oversaw safety issues relating to Amgen’s products.
`
`
`
`- 1 -
`
`
`
`Page 2 of 5
`
`
`
`
`
`
`
`
`
`5.
`
`In 1986, I received a degree in pharmacology form the University of
`
`Leeds in Leeds, United Kingdom. Subsequently, I received a post graduate
`
`diploma (1989) in Clinical Science and a Master’s Degree in Clinical Research
`
`(1998), both from the Welsh School of Pharmacy, University of Wales, Cardiff,
`
`United Kingdom. I also received a law degree from the College of Law in London
`
`in 2003.
`
`6.
`
`I am familiar with the restricted-distribution system known as the
`
`System for Thalidomide Education and Prescribing Safety, or S.T.E.P.S.®
`
`S.T.E.P.S.® was introduced with Celgene’s Thalomid® brand thalidomide capsules
`
`in July of 1998.
`
`7.
`
`Since July of 1998, there has not been a single birth defect in
`
`connection with Thalomid®, in the United States or elsewhere. There have also
`
`been zero birth defects associated with two of Celgene’s other products, Revlimid®
`
`and Pomalyst®, both of which are believed to be teratogenic by the U.S. Food and
`
`Drug Administration.
`
`8.
`
`Several materials associated with the original, 1998 S.T.E.P.S.®
`
`program are described below.
`
`
`
`- 2 -
`
`
`
`Page 3 of 5
`
`
`
`
`
`II.
`
`S.T.E.P.S.® MATERIALS
`
`
`
`
`
`9.
`
`Exhibit 2062 is a true and correct copy of the Pharmacy Registration
`
`Card that was used and distributed by Celgene in connection with the original
`
`S.T.E.P.S.® program.
`
`10. Exhibit 2063 is a true and correct copy of the Dear Pharmacist Letter
`
`that was used and distributed by Celgene in connection with the original
`
`S.T.E.P.S.® program.
`
`11. Exhibit 2064 is a true and correct copy of the template for the “Dear
`
`Dr.” letter that was used and distributed by Celgene in connection with the original
`
`S.T.E.P.S.® program. The name of each registered physician, along with the name
`
`and phone number of the Celgene Immunology Specialist, were added to each
`
`letter before the letter was sent to each registered physician.
`
`12. Exhibit 2065 is a true and correct copy of the Patient Registration
`
`Form that was used and distributed by Celgene in connection with the original
`
`S.T.E.P.S.® program.
`
`13. Exhibit 2066 is a true and correct copy of the Instructions for
`
`Physicians that were used and distributed by Celgene in connection with the
`
`original S.T.E.P.S.® program.
`
`
`
`
`
`- 3 -
`
`
`
`Page 4 of 5
`
`
`
`
`
`
`
`
`
`Executed this 12th day of February 2016. I declare under penalty of perjury
`
`that the foregoing is true and correct.
`
`
`
`
`
`
`
`
`
`- 4 -
`
`Page 5 of 5